Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitoxantrone hydrochloride liposome (CSPC ZhongQi Pharmaceutical Technology)
- Development stage
- Unknown
- Lead developer
- CSPC ZhongQi Pharmaceutical Technology
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Mitoxantrone hydrochloride liposome (Lipo-MIT) is a nano-drug formulation of mitoxantrone, an anthracycline drug. It is a liposomal preparation designed to provide higher anti-cancer efficacy and lower toxicity compared to conventional mitoxantrone through modified drug release and distribution. Lipo-MIT has been approved in China for the treatment of relapsed or refractory peripheral T-cell lymphoma and has shown promising results in clinical trials for advanced breast cancer and relapsed/refractory acute myeloid leukemia.
- Other names
- mitoxantrone hydrochloride liposome injection
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on mitoxantrone hydrochloride liposome (CSPC ZhongQi Pharmaceutical Technology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitoxantrone hydrochloride liposome (CSPC ZhongQi Pharmaceutical Technology).